These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35364599)

  • 1. Achieving Antiretroviral Therapy Uptake and Viral Suppression Among Children and Adolescents Living With HIV in the UNAIDS 90-90-90 Era Across Six Countries in Eastern and Southern Africa-Lessons From the BIPAI Network.
    Bacha JM; Dlamini S; Anabwani F; Gwimile J; Kanywa JB; Farirai J; Bvumbwe M; Steffy T; Nguyen D; Wanless RS; Haq H
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):300-308. PubMed ID: 35364599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa.
    Bacha JM; Dlamini S; Anabwani F; Gwimile J; Kanywa JB; Farirai J; Bvumbwe M; Tsotako M; Steffy T; Nguyen D; Mendez-Reyes JE; Elyanu P; Haq H
    Pediatr Infect Dis J; 2023 Jul; 42(7):576-581. PubMed ID: 36795586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and predictors of virological failure among HIV infected children and adolescents receiving second-line antiretroviral therapy in Uganda, a retrospective study.
    Musiime-Mwase F; Nakanjako D; Kanywa JB; Nasuuna EM; Naitala R; Oceng R; Sewankambo N; Elyanu P
    BMC Infect Dis; 2024 Sep; 24(1):1057. PubMed ID: 39333946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing multimonth dispensing of antiretrovirals and assessing the effect on viral load suppression among children and adolescents receiving HIV services in Nigeria.
    Casalini C; Bateganya M; Akolo C; Sanwo O; Idemudia A; Nwaokoro P; Eyam F; Ogbechie MD; Obiora-Okafo C; Oduola A; Wilcher R; Mack N; Khamofu H; Pandey SR
    PLoS One; 2023; 18(6):e0286303. PubMed ID: 37315075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Associated With Viral Suppression and Drug Resistance in Children and Adolescents Living With HIV in Care and Treatment Programs in Southern Tanzania.
    Khamadi SA; Bahemana E; Dear N; Mavere C; George F; Kapene R; Papianus G; Willoughby W; Chambers J; Ganesan K; Mwakabanje I; Bacha JM; Desai P; Almas S; Coakley PD; Wolfman V; Lee EH; Hickey PW; Livezey J; Agaba PA
    J Pediatric Infect Dis Soc; 2023 Jun; 12(6):353-363. PubMed ID: 37279560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration.
    Jiamsakul A; Kariminia A; Althoff KN; Cesar C; Cortes CP; Davies MA; Do VC; Eley B; Gill J; Kumarasamy N; Machado DM; Moore R; Prozesky H; Zaniewski E; Law M
    J Acquir Immune Defic Syndr; 2017 Nov; 76(3):319-329. PubMed ID: 28708808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of viral load non-suppression among adolescents in Mbale District, Eastern Rural Uganda.
    Maena J; Banke-Thomas A; Mukiza N; Kuteesa CN; Kakumba RM; Kataike H; Kizito S; Babirye JA; Nakalega R
    AIDS Res Ther; 2021 Dec; 18(1):91. PubMed ID: 34863196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda.
    Nasuuna E; Kigozi J; Babirye L; Muganzi A; Sewankambo NK; Nakanjako D
    BMC Public Health; 2018 Aug; 18(1):1048. PubMed ID: 30134880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Standardized Pediatric Expedited Encounters for ART Drugs Initiative (SPEEDI): description and evaluation of an innovative pediatric, adolescent, and young adult antiretroviral service delivery model in Tanzania.
    Bacha JM; Aririguzo LC; Mng'ong'o V; Malingoti B; Wanless RS; Ngo K; Campbell LR; Schutze GE
    BMC Infect Dis; 2018 Sep; 18(1):448. PubMed ID: 30176821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi.
    Makonokaya L; Maida A; Kalitera LU; Wang A; Kapanda L; Kayira D; Bottoman M; Nkhoma H; Dunga S; Joaki Z; Chamanga R; Nkanaunena K; Hrapcak S; Nyirenda R; Chiwandira B; Maulidi M; Woelk G; Machekano R; Maphosa T
    AIDS Behav; 2024 Jun; 28(6):2148-2155. PubMed ID: 38615099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE): study protocol of an open-label randomised clinical trial in children and adolescents living with HIV in Lesotho and Tanzania.
    Brown JA; Ringera I; Luoga E; Cheleboi M; Kimera N; Muhairwe J; Kayembe BP; Molapo Hlasoa M; Kabundi L; Yav CWD; Mothobi B; Thahane L; Amstutz A; Bachmann N; Mollel GJ; Bresser M; Glass TR; Paris DH; Klimkait T; Weisser M; Labhardt ND
    BMC Infect Dis; 2020 Oct; 20(1):773. PubMed ID: 33076866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cross-sectional Population-based HIV Impact Assessment surveys.
    Teasdale CA; Zimba R; Abrams EJ; Sachathep K; Ndagije F; Nuwagaba-Biribonwoha H; Musuka G; Mugurungi O; Maile L; Mahy M; Low A
    Lancet HIV; 2022 Feb; 9(2):e91-e101. PubMed ID: 35120641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis symptom screening for children and adolescents living with HIV in six high HIV/TB burden countries in Africa.
    Vonasek B; Kay A; Devezin T; Bacha JM; Kazembe P; Dhillon D; Dlamini S; Haq H; Thahane L; Simon K; Matshaba M; Sanders J; Minde M; Wanless S; Nyasulu P; Mandalakas A
    AIDS; 2021 Jan; 35(1):73-79. PubMed ID: 33048868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for Closing the Gap in HIV Diagnosis, Treatment, and Viral Load Suppression in Children in Malawi: Results From a 2015-2016 Population-based HIV Impact Assessment Survey.
    Jonnalagadda S; Auld A; Jahn A; Saito S; Bello G; Sleeman K; Ogollah FM; Cuervo-Rojas J; Radin E; Kayira D; Kim E; Payne D; Burnett J; Hrapcak S; Patel H; Voetsch AC;
    Pediatr Infect Dis J; 2021 Nov; 40(11):1011-1018. PubMed ID: 34382613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries.
    Han WM; Law MG; Egger M; Wools-Kaloustian K; Moore R; McGowan C; Kumarasamy N; Desmonde S; Edmonds A; Davies MA; Yiannoutsos C; Althoff KN; Cortes CP; Mohamed TJ; Jaquet A; Anastos K; Euvrard J; Castelnuovo B; Salters K; Coelho LE; Ekouevi DK; Eley B; Diero L; Zaniewski E; Ford N; Sohn AH; Kariminia A;
    Lancet HIV; 2021 Dec; 8(12):e766-e775. PubMed ID: 34856180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rates of antiretroviral coverage and virological suppression in HIV-1-infected children and adolescents.
    Soumah A; Avettand-Fenoel V; Veber F; Moshous D; Mahlaoui N; Blanche S; Frange P
    Med Mal Infect; 2020 May; 50(3):269-273. PubMed ID: 31722862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimonth Prescription of Antiretroviral Therapy Among Children and Adolescents: Experiences From the Baylor International Pediatric AIDS Initiative in 6 African Countries.
    Kim MH; Wanless RS; Caviness AC; Golin R; Amzel A; Ahmed S; Mhango J; Damba D; Kayabu A; Chodota M; Dlamini S; Chidah N; Mokhali M; Calles NR; Abrams EJ
    J Acquir Immune Defic Syndr; 2018 Aug; 78 Suppl 2(Suppl 2):S71-S80. PubMed ID: 29994828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to antiretroviral therapy in HIV-infected children aged 0-19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004-2015: A prospective cohort study.
    Desmonde S; Tanser F; Vreeman R; Takassi E; Edmonds A; Lumbiganon P; Pinto J; Malateste K; McGowan C; Kariminia A; Yotebieng M; Dicko F; Yiannoutsos C; Mubiana-Mbewe M; Wools-Kaloustian K; Davies MA; Leroy V;
    PLoS Med; 2018 May; 15(5):e1002565. PubMed ID: 29727458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic non-suppression and early loss to follow up among pregnant and non-pregnant adolescents aged 15-19 years initiating antiretroviral therapy in South Africa: a retrospective cohort study.
    Nyakato P; Schomaker M; Fatti G; Tanser F; Euvrard J; Sipambo N; Fox MP; Haas AD; Yiannoutsos CT; Davies MA; Cornell M
    J Int AIDS Soc; 2022 Jan; 25(1):e25870. PubMed ID: 35032096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proportion of loss to follow-up from antiretroviral therapy (ART) and its association with age among adolescents living with HIV in sub-Saharan Africa: A systematic review and meta-analysis.
    Leshargie CT; Demant D; Burrowes S; Frawley J
    PLoS One; 2022; 17(8):e0272906. PubMed ID: 35951621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.